医学通信公司
期刊
会议
图书
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2019, Vol.61 (1578)医学通信公司
摘要:The FDA has approved Jornay PM (Ironshore), a capsule formulation of methylphenidate with a delayed-release outer layer and an extended-release inner layer, for once-nightly treatment of attention-deficit hyperactivity disorder (ADHD) in patients >6 years old. Jornay PM is the fi...
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2019, Vol.61 (1578)医学通信公司
摘要:Anxiety disorders (generalized anxiety disorder, panic disorder, social anxiety disorder, and various phobias) are the most common form of psychiatric illness. They can be treated effectively with cognitive behavioral therapy (CBT) and/or pharmacotherapy. Obsessive-compulsive dis...
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2019, Vol.61 (1577)医学通信公司
摘要:The FDA has approved bremelanotide (Vyleesi – Amag), a melanocortin receptor agonist, for subcutaneous treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). Bremelanotide is not approved for use in men or postmenopausal women. ...
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2019, Vol.61 (1577)医学通信公司
摘要:In our article on Bijuva, the oral fixed-dose combination of estradiol and progesterone (Med Lett Drugs Ther 2019; 61:99), Table 1 should have included single-ingredient oral formulations of estradiol and progesterone (see below). They will be added to the table as it appears onl...
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2019, Vol.61 (1577)医学通信公司
摘要:The FDA has approved onasemnogene abeparvovec-xioi (Zolgensma – Avexis), an adeno-associated virus vector-based gene therapy, for one-time IV treatment of children
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2019, Vol.61 (1577)医学通信公司
摘要:The FDA has approved cladribine (Mavenclad – EMD Serono), a purine antimetabolite, for oral treatment of adults with relapsing forms of multiple sclerosis (MS), including relapsing-remitting disease and active secondary progressive MS (SPMS), who cannot tolerate or have had ...
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2019, Vol.61 (1577)医学通信公司
摘要:The FDA has approved cyclosporine 0.09% ophthalmic solution (Cequa – Sun) to increase tear production in patients with keratoconjunctivitis sicca (dry eye disease). Restasis, a 0.05% cyclosporine emulsion, was approved in the US in 2003 for the same indication.
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2019, Vol.61 (1576)医学通信公司
摘要:Smoking tobacco remains the primary preventable cause of death in the US. Smoking cessation often requires both pharmacotherapy and behavioral support.
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2019, Vol.61 (1576)医学通信公司
摘要:The FDA has approved Apadaz (KemPharm), a short-acting, fixed-dose combination of benzhydrocodone and acetaminophen, for short-term management (≤14 days) of acute pain severe enough to require an opioid and for which alternative treatment options are inadequate. Benzhydrocod...
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2019, Vol.61 (1576)医学通信公司
摘要:View the Expanded Table: Some Drugs for Smoking Cessation

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×